MKI67 and breast disorder: Radiomics has made great progress in many fields, and recent studies have explored the use of radiomics features in breast diseases, including distinguishing benign and malignant lesions (9), predicting the immunohistochemistry and status of Ki-67 (10, 11), calculating the state of sentinel lymph nodes (12), detecting the effect of neoadjuvant therapy and determining the risk of recurrence (13, 14), which were focused on female breast diseases; few existing studies have evaluated male benign or malignant breast lesions by radiomics.